New drug combo targets Hard-to-Treat cancers in early trial

NCT ID NCT07231458

Recruiting now Disease control Sponsor: Abalos Therapeutics GmbH Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests an experimental drug called ABX-001, given alone or with the immunotherapy pembrolizumab, in 27 people with advanced solid tumors who have no standard treatment options left. The main goal is to check safety and find the right dose, while also looking for any signs that the tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABX-001 (an experimental drug) and pembrolizumab (an immunotherapy)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early (Phase 1) trial with only 27 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Charite-Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF)
RECRUITING

Berlin, 12200, Germany
Hospital Universitario Fundacion Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
The START Center for Cancer Care - CIOCC
RECRUITING

Madrid, 28050, Spain
Universitaetsklinikum Tuebingen
RECRUITING

Tübingen, 72076, Germany
Vall d'Hebron Institut d'Oncologia
RECRUITING

Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.